ts 12 years of age and older. treatment should be limited to 2 consecutive weeks, and the total dosage should not exceed 50 grams per week. 1.2 moderate to severe plaque-type psoriasis clobetasol propionate cream, 0.05% (emollient) is indicated for the topical treatment of moderate to severe plaque-type psoriasis. treatment beyond 4 consecutive weeks is not recommended. use in pediatric patients under 16 years of age is not recommended. 1.3 limitations of use clobetasol propionate cream, 0.05% (emollient) should not be used in the treatment of rosacea or perioral dermatitis, and should not be used on the face, groin, or axillae. the total dosage should not exceed 50 grams per week. avoid use if skin atrophy is present at the treatment site.

topical corticosteroid that has been shown to suppress the hpa axis at doses as low as 2 grams per day. systemic absorption of topical corticosteroids can produce reversible hpa axis suppression with the potential for clinical glucocorticosteroid insufficiency. this may occur during treatment or upon withdrawal of the topical corticosteroid. because of the potential for systemic absorption, use of topical corticosteroids may require that patients be periodically evaluated for hpa axis suppression. in a study including 12 subjects ages 18 years and older with psoriasis or atopic dermatitis involving at least 30% body surface area (bsa), adrenal suppression was identified in 3 out of 12 subjects (25%) following 1 week of treatment. factors that predispose a patient using a topical corticosteroid to hpa axis suppression include the use of more potent steroids, use over large surface areas, use over prolonged periods, use under occlusion, use on an altered skin barrier, and use in patients with liver failure. an acth stimulation test may be helpful in evaluating patients for hpa axis suppression. if hpa axis suppression is documented, an attempt should be made to gradually withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid. manifestations of adrenal insufficiency may require supplemental systemic corticosteroids. recovery of hpa axis function is generally prompt and complete upon discontinuation of topical corticosteroids. cushing's syndrome, hyperglycemia, and unmasking of latent diabetes mellitus can also result from systemic absorption of topical corticosteroids. use of more than one corticosteroid-containing product at the same time may increase the total systemic corticosteroid exposure. pediatric patients may be more susceptible to systemic toxicity from use of topical corticosteroids [see use in specific populations ( 8.4 )] . 5.2 local adverse reactions with topical corticosteroids local adverse reactions may be more likely to occur with occlusive use, prolonged use or use of higher potency corticosteroids. reactions may include atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, hypertrichosis, perioral dermatitis, allergic contact dermatitis, secondary infection, and miliaria. some local adverse reactions may be irreversible. clobetasol propionate is not recommended in patients with acne vulgaris, rosacea or perioral dermatitis. 5.3 allergic contact dermatitis allergic contact dermatitis with corticosteroids is usually diagnosed by observing a failure to heal rather than noting a clinical exacerbation. clinical diagnosis of allergic contact dermatitis can be confirmed with patch testing. if irritation develops, clobetasol propionate cream, 0.05% (emollient) should be discontinued and appropriate therapy instituted. 5.4 concomitant skin infections if concomitant skin infections are present or develop, an appropriate antifungal or antibacterial agent should be used. if a favorable response does not occur promptly, use of clobetasol propionate cream, 0.05% (emollient) should be discontinued until the infection has been adequately controlled.

ropionate cream, 0.05% (emollient) should not be used with occlusive dressings. apply a thin layer of clobetasol propionate cream, 0.05% (emollient) to the affected skin areas twice daily and rub in gently and completely. ( 2 ) treatment should be limited to 2 consecutive weeks, and amounts greater than 50 grams per week should not be used. ( 2 ) in moderate to severe plaque-type psoriasis, clobetasol propionate cream, 0.05% (emollient) applied to 5% to 10% of body surface area can be used for up to 4 weeks. the total dosage should not exceed 50 grams per week. when dosing for more than 2 weeks, any additional benefit of extending treatment should be weighed against the risk of hpa suppression. ( 2 )

ness in the elbow, skin atrophy, and telangiectasia. the incidence of local adverse reactions reported in the trials with clobetasol propionate cream, 0.05% (emollient) was less than 2% of patients treated with the exception of burning/stinging which occurred in 5% of treated patients.

ls tested down to 0.03 mg/kg. these doses are approximately 0.33 and 0.01 times, respectively, the human topical dose of clobetasol propionate cream, 0.05% (emollient). abnormalities seen included cleft palate and skeletal abnormalities. in rabbits, clobetasol propionate was teratogenic at doses of 3 and 10 mcg/kg. these doses are approximately 0.001 and 0.003 times, respectively, the human topical dose of clobetasol propionate cream, 0.05% (emollient). abnormalities seen included cleft palate, cranioschisis, and other skeletal abnormalities. 8.3 females and males of reproductive potential systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. it is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. because many drugs are excreted in human milk, caution should be exercised when clobetasol propionate cream, 0.05% (emollient) is administered to a nursing woman. 8.4 pediatric use safety and effectiveness of clobetasol propionate cream, 0.05% (emollient) in pediatric patients have not been established and its use in pediatric patients under 12 years of age is not recommended. in a study including 12 subjects ages 18 years and older with psoriasis or atopic dermatitis involving at least 30% body surface area (bsa), adrenal suppression was identified in 3 out of 12 subjects (25%) following 1 week of treatment. four-week hpa axis suppression studies with clobetasol propionate cream, 0.05% (emollient) in pediatric subjects have not been conducted. because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of hpa axis suppression and cushing's syndrome when they are treated with topical corticosteroids. they are therefore also at greater risk of glucocorticosteroid insufficiency during or after withdrawal of treatment. adverse effects including striae have been reported with inappropriate use of topical corticosteroids in infants and children. hpa axis suppression, cushing's syndrome, linear growth retardation, delayed weight gain, and intracranial hypertension have been reported in children receiving topical corticosteroids. manifestations of adrenal suppression in children include low plasma cortisol levels and absence of response to acth stimulation. manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. the use of clobetasol propionate cream, 0.05% (emollient) for 4 consecutive weeks has not been studied in pediatric patients under 16 years of age. 8.5 geriatric use clinical studies of clobetasol propionate cream, 0.05% (emollient) did not include sufficient numbers of subjects aged 65 and older to determine whether they respond differently from younger subjects. in general, dose selection for an elderly patient should be cautious.

these doses are approximately 0.33 and 0.01 times, respectively, the human topical dose of clobetasol propionate cream, 0.05% (emollient). abnormalities seen included cleft palate and skeletal abnormalities. in rabbits, clobetasol propionate was teratogenic at doses of 3 and 10 mcg/kg. these doses are approximately 0.001 and 0.003 times, respectively, the human topical dose of clobetasol propionate cream, 0.05% (emollient). abnormalities seen included cleft palate, cranioschisis, and other skeletal abnormalities.

topical corticosteroids in infants and children. hpa axis suppression, cushing's syndrome, linear growth retardation, delayed weight gain, and intracranial hypertension have been reported in children receiving topical corticosteroids. manifestations of adrenal suppression in children include low plasma cortisol levels and absence of response to acth stimulation. manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. the use of clobetasol propionate cream, 0.05% (emollient) for 4 consecutive weeks has not been studied in pediatric patients under 16 years of age.

ce. 12.3 pharmacokinetics the extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle and the integrity of the epidermal barrier. topical corticosteroids can be absorbed from normal intact skin. inflammation and/or other disease processes in the skin may increase percutaneous absorption.

ctor you are using clobetasol propionate cream, 0.05% (emollient). do not use clobetasol propionate cream, 0.05% (emollient) on the face, underarms or groin areas. as with other corticosteroids, therapy should be discontinued when control is achieved. if no improvement is seen within 2 weeks, contact the physician. use no more than 50 grams per week of clobetasol propionate cream, 0.05% (emollient). store between 59°f and 86°f (15°c and 30°c). do not refrigerate. manufactured by: ani pharmaceuticals canada, inc. oakville, on l6h 1m5 canada distributed by: ani pharmaceuticals, inc. baudette, mn 56623 n3015 rev 09/20 logo